Back
Dentsply Sirona 10K Form
Sell
29
XRAY
Dentsply Sirona
Last Price:
37.10
Seasonality Move:
-0.23%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2020-11-05 | 10Q | XRAY/Dentsply Sirona Quarterly |
2020-08-06 | 10Q | XRAY/Dentsply Sirona Quarterly |
2020-05-11 | 10Q | XRAY/Dentsply Sirona Quarterly |
2020-03-02 | 10K | XRAY/Dentsply Sirona Annual |
2019-11-07 | 10Q | XRAY/Dentsply Sirona Quarterly |
2019-08-02 | 10Q | XRAY/Dentsply Sirona Quarterly |
Receive XRAY News And Ratings
See the #1 stock for the next 7 days that we like better than XRAY
XRAY Financial Statistics
Sales & Book Value
Annual Sales: | $4.25B |
---|---|
Cash Flow: | $49M |
Price / Cash Flow: | 14.83 |
Annual Sales: | $22.77 |
Price / Book: | 1.62 |
Profitability
EPS (TTM): | 1.69000 |
---|---|
Net Income (TTM): | $369M |
Gross Margin: | $2.36B |
Return on Equity: | 7.36% |
Return on Assets: | 4% |
Dentsply Sirona Earnings Forecast
Key Dentsply Sirona Financial Ratios
- The Gross Profit Margin over the past 36 years for XRAY is 55.54%.
- The Selling, General & Administrative Expenses for XRAY have been equal to 36.49% of Gross Profit Margin.
- The Research & Development expenses have been 4.02% of Revenue.
- The Interest Expense is 13.06% of Operating Income.
- The Net Earning history of XRAY is 9.90% of Total Revenues.
- Per Share Earnings over the last 36 years have been positive in 23 years.
Dentsply Sirona Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | S&P500 |
---|---|
Industry: | Medical Instruments & Supplies |
Sector: | Healthcare |
Current Symbol: | XRAY |
CUSIP: | 24906P |
Website: | dentsplysirona.com |
Debt
Debt-to-Equity Ratio: | 0.45 |
---|---|
Current Ratio: | 1.45 |
Quick Ratio: | 0.83 |
Price-to-Earnings
Trailing P/E Ratio: | 19.29 |
---|---|
Forward P/E Ratio: | 13.88 |
XRAY Technical Analysis vs Fundamental Analysis
Sell
29
Dentsply Sirona (XRAY)
is a Sell
Is Dentsply Sirona a Buy or a Sell?
-
Dentsply Sirona stock is rated a Sell
The current Dentsply Sirona [XRAY] share price is $36.84. The Score for XRAY is 29, which is 42% below its historic median score of 50, and infers higher risk than normal.